Project Grant R01DK140433
- Federal Grant Award Summary Duke University's Office of Research Administration received a $318,972 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective April 1, 2026 through January 31, 2029. The grant funds a two-phase clinical trial investigating the role of phosphate levels in acute pancreatitis, a severe inflammatory pancreatic disorder affecting...
- The National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases awarded $3.6 million under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Anagram Therapeutics Inc. to develop a novel pancreatic enzyme replacement therapy. Specifically, Anagram will engineer lipase enzymes for improved stability against low pH and proteolytic degradation. This will allow for effective digestion of fats in both the stomach and small...
- The University of Iowa received a $655,482 Project Grant awarded March 5, 2026, by the National Institute of Diabetes and Digestive and Kidney Diseases under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant supports basic biomedical research investigating the role of the Notch signaling pathway in chronic pancreatitis (CP) pathogenesis, with a performance period extending through December 31, 2029. The research focuses on elucidating mechanisms by...
- This $370,575 project grant from the National Institutes of Health National Cancer Institute Cancer Biology Research program (CFDA 93.396) will fund research at the University of Cincinnati investigating the molecular mechanisms of growth in pancreatic cancer with GNAS mutations. The grant supports studies from August 1, 2022 to July 31, 2027 to further the understanding of the oncogenic functions of mutant GNAS and its downstream signaling pathways. Specifically, the research will illuminate...
- Federal Project Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases awarded University of California, Irvine a project grant of $169,388 (awarded September 9, 2025, with completion targeted July 31, 2030) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). This research project will investigate fatty acid amide hydrolase (FAAH)-regulated endocannabinoid signaling as a novel, opioid-sparing therapeutic approach for...
- Summary of Cooperative Agreement Award The University of California, San Francisco received a $816,325 Cooperative Agreement from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded August 1, 2025, with completion expected June 30, 2029. This collaborative research initiative focuses on the development and optimization of next-generation Protein-Induced ER Protein (PAIR)...
- Project Grant Award Summary Weill Medical College of Cornell University received a $859,704 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective July 2, 2025, with a completion date of April 30, 2029. The research focuses on elucidating the role of AGR2 (anterior gradient 2), an endoplasmic reticulum protein disulfide isomerase, in regulating...
- This $667,118 Project Grant was awarded on April 1, 2025 by the National Cancer Institute (CFDA 93.396 Cancer Biology Research) to The Regents of the University of California, San Francisco (UCSF) to conduct research aimed at "Identifying and Disabling New Pathways for Macromolecular Recycling in Pancreatic Cancer". The project will focus on studying the role of key lysosomal factors, including PLBD1 and LGMN, that are essential for the survival and growth of pancreatic ductal...
- Federal Project Grant Award Summary Nous Biosciences Inc. received a $716,078 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct research on combination therapeutic treatment for murine colitis. The award, dated September 3, 2025, with completion targeted for August 31, 2026, supports preclinical research investigating the combined use of...
- This $2.1 million Project Grant was awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to The Regents of the University of Colorado-Denver for the period September 15, 2025 through September 14, 2029. The research project investigates the role of mitochondrial dysfunction in Paneth cells as a mediator of inflammatory bowel disease (IBD), specifically examining how...
ELUCIDATING NOVEL MECHANISMS FOR PANCREATITIS THROUGH CALCINEURIN SIGNALING - PROJECT SUMMARY. ACUTE PANCREATITIS (AP) IS AN EXQUISITELY PAINFUL, LIFE-THREATENING, PUBLIC HEALTH PROBLEM THAT HAS SUBSTANTIAL MORBIDITY AND LIMITED TREATMENT MODALITIES. OUR LONG-TERM GOAL IS TO DEVELOP FOCUSED THERAPIES TO TREAT AP AND MITIGATE DISEASE SEVERITY. THE PREMISE IS BASED ON OUR DISCOVERY (1) THAT THE CALCIUM-ACTIVATED PHOSPHATASE CALCINEURIN (CN) IS A POTENT MEDIATOR OF AP IN THE PRIMARY PARENCHYMAL CELL OF THE PANCREAS, THE ACINAR CELL, AND (2) THAT THE DISTINCT MOLECULAR SIGNATURES UNDERLYING THIS POTENT EFFECT CAN BE LEVERAGED TO DEVELOP TARGETED THERAPIES FOR AP. THE TWO MAJOR OBJECTIVES OF THE CURRENT PROPOSAL ARE (1) TO ELUCIDATE THE CN-MODULATED SIGNALING PATHWAYS IN AP AND (2) TO IDENTIFY NOVEL AND POTENTIALLY THERAPEUTICALLY TARGETABLE, DIRECT CN SUBSTRATES WITHIN THESE PATHWAYS. THE THREE SPECIFIC AIMS ARE TO: (1) DEFINE THE PHOSPHOSIGNALING NETWORKS, INCLUDING SIGNATURES REGULATED BY CN ACTIVITY IN AP THROUGH PHOSPHOPROTEOMICS COUPLED WITH POWERFUL BIOINFORMATICS; (2) CHARACTERIZE THE ROLE OF CN IN THE IDENTIFIED PATHWAYS OF MTOR AND AUTOPHAGY DURING AP; AND (3) EVALUATE NOVEL CN SUBSTRATE CANDIDATES THAT ARE INTEGRAL TO THE IDENTIFIED PATHWAYS. OUR HYPOTHESIS, WHICH WAS GENERATED FROM COMPELLING PRELIMINARY PHOSPHOPROTEOMIC DATA, IS THAT CN MEDIATES AP BY IMPAIRING AUTOPHAGY, AND THE MECHANISM FOR THE IMPAIRMENT IS THROUGH BOTH (1) ACTIVATION OF THE UPSTREAM AUTOPHAGY INHIBITOR MTOR AND (2) DIRECT INHIBITION OF CN SUBSTRATES IN THE AUTOPHAGY PATHWAY ITSELF. THE DESIGN OF THE APPROACH IS THAT AIM 1 IS AN UNBIASED PHOSPHOPROTEOMIC SCREEN, USING CLINICALLY AND BIOLOGICALLY RELEVANT AP CONDITIONS, FOR PHOSPHOSIGNALS THAT WILL PROVIDE CLUES TO CN-MODULATED PATHWAYS IN AP. AIM 2 IS TO CONDUCT INDEPENDENT, EMPIRICAL TESTING OF CN MODULATION IN AP OF THE IDENTIFIED PATHWAYS OF AUTOPHAGY AND MTOR, BY EXAMINING CANONICAL COMPONENTS AND PHOSPHOSITES, INCLUDING THE ONES THAT WERE NOT NECESSARILY DETECTED IN THE UNBIASED PHOSPHOPROTEOMIC DATA. AIM 3 IS A SYSTEMATIC IDENTIFICATION, FOLLOWED BY BIOCHEMICAL VALIDATION, OF NOVEL CN SUBSTRATES THAT ARE INTEGRAL TO THE IDENTIFIED PATHWAYS IN AP. HERE, WE WILL ALSO PROBE THE MOLECULAR MECHANISMS BY WHICH CN MODULATES NOVEL SUBSTRATE ACTIVITY AND FUNCTION. INCORPORATING A HIGHLY MULTIDISCIPLINARY TEAM OF INVESTIGATORS AND AN IDEALLY SUITED ENVIRONMENT, THE PROPOSED STUDIES ARE TECHNOLOGICALLY AND CONCEPTUALLY INNOVATIVE SINCE THEY UTILIZE (1) ADVANCED COMPUTATIONAL METHODS TO IDENTIFY CN-REGULATED PATHWAYS AND SUBSTRATES, (2) HUMAN PANCREAS SPECIMENS FOR EX VIVO CULTURE, (3) AN INNOVATIVE IN VIVO PRESSURE-INDUCED PANCREATITIS (PIP) MODEL, AND (4) CUTTING EDGE PHOSPHOPROTEOMIC AND BIOCHEMICAL TOOLS INCLUDING BIOID, WHICH CAPTURES IN CELL TRANSIENT LOW-AFFINITY INTERACTIONS BETWEEN CN AND ITS SUBSTRATE CANDIDATES. THE SIGNIFICANCE OF THE PROPOSAL IS THAT IT CREATES A DISCOVERY PIPELINE TO IDENTIFY NOVEL CN-MODULATED PHOSPHOSIGNALING NETWORKS IN AP AND WILL PROVIDE A VALUABLE RESOURCE TO THE PANCREAS COMMUNITY THAT WILL AID IN DEVISING TARGETED AP THERAPIES.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $606.8k | 7/7/25 | ||
| Not listed | $620.4k | 7/23/24 |
GrantNumber | Description | Subgrantee | Prime Award | Dollars Obligated | Updated At |
|---|---|---|---|---|---|
63566871317273S | University Of California, LOS Angeles | Project Grant R01DK140433 | $60.3k | 10/28/25 |